WASHINGTON, July 12 /PRNewswire/ -- GlaxoSmithKline (GSK) Consumer
Healthcare is marking the 10th anniversary of when therapeutic nicotine
(TN) products became available over-the-counter (OTC) at the 13th World
Conference on Tobacco OR Health (WCTOH). GSK's therapeutic nicotine
products have helped more than five million smokers around the world
successfully quit using safe and effective stop-smoking aids. Yet, there is
a significant need to encourage and educate the more than 1.3 billion
current smokers around the world on how to quit successfully. Shifts in
public policy like smoke-free laws and cigarette tax increases are
encouraging more and more smokers to attempt quitting. It is important that
those smokers have access to counseling, behavioral support programs, and
FDA-approved safe and effective stop-smoking products. At the conference,
GSK will highlight the latest support resources available to smokers.
"Over the past decade, GSK has made tremendous progress by helping
millions of smokers quit successfully and live longer tobacco-free lives,"
said Katie Kemper, vice president, GSK Global Smoking Control. "But our job
is far from over. Smokers must understand that there is no magic pill.
Smokers and health care professionals need to know that successful quit
attempts require breaking the addiction to nicotine and modifying
International guidelines from the United States, United Kingdom and the
World Health Organization (WHO) recommend TN as a first-line treatment for
smoking addiction. Quitters using therapeutic nicotine can double their
chances of success versus quitting without help. Therapeutic nicotine
products like Nicorette(R) gum, NicoDerm(R) CQ(R) patch and Commit(R)
lozenge, are available in more than 35,000 retail outlets in the United
States and under the NiQuitin brand name in other countries. These stop
smoking aids are designed specifically to break the daily addiction cycle
by offering a gradual, controlled delivery of nicotine to the body, helping
to relieve cravings and withdrawal symptoms.
"Many smokers wrongly believe they can simply put down their cigarettes
and walk away forever," said Saul Shiffman, PhD, world-renowned researcher
and professor in the departments of psychology and pharmaceutical science
at the University of Pittsburgh. "What smokers don't realize is while the
body clears nicotine relatively quickly the effects of nicotine can last
for months. Therapeutic nicotine helps safely reduce cravings so a smoker
can wean himself off nicotine gradually, allowing him to focus on changing
Nicotine Addiction + Habit Change
Research shows that one-third of all quit attempts fail within 48
hours. Nicotine withdrawal will lead to desperate cravings that are hard to
overcome with willpower alone. Therapeutic nicotine releases temporary,
controlled low doses of nicotine in a steady stream that ends gradually and
it helps to relieve cravings by teaching the brain to live with less
nicotine and then eventually no nicotine.
Tobacco-delivered nicotine re-programs and trains their brain to
connect daily routines with familiar cravings to sustain certain levels of
nicotine. Everyday activities trigger the urge to smoke, such as drinking
coffee in the morning, talking on the phone, taking a break at work, and
driving. During these times, cravings for a cigarette are actually the
brain looking for an intake of nicotine. Therapeutic nicotine relieves
these intense cravings, as it gives the brain exactly what it needs. It
reduces intense cravings and withdrawal symptoms, helping quitters more
Safety and Efficacy of Therapeutic Nicotine
Therapeutic nicotine is extensively proven to reduce and often
eliminate cravings during quitting, allowing smokers to focus on behavior
change. More than 110 studies involving tens of thousands of participants
have demonstrated the safety of therapeutic nicotine, even in populations
with specific health conditions, such as diabetes, high blood pressure,
lung disease, and existing heart disease.
Additional Smoking Cessation Resources
Because quitting cigarettes also requires behavior change, GSK Consumer
Healthcare offers smokers a variety of customized resources to help smokers
and non-smokers understand and address smoking cessation and address habits
formed from smoking. GSK also actively supports government policies which
are proven to motivate smokers to quit, such as comprehensive clean indoor
air legislation and other measures recommended by the Framework Convention
on Tobacco Control.
Committed Quitters is the only free, tailored Web-based behavioral
support program that has been proven to increase a smoker's chances of
quitting. This program is available as Click2Quit in the UK. Participants
receive a customized smoking cessation plan after completing an online
questionnaire that gathers information about their habits, behaviors, and
motivations for smoking and quitting. The program provides coping
strategies, advice, and incentives to stay smoke-free, and has been
evaluated in a randomized controlled clinical trial and shown to increase a
quitter's chances by almost 30 percent. For more information, visit
GSK offers smoking cessation counselors to counsel patients five days a
week by calling 1-877-NO ASHES in the U.S.
About GlaxoSmithKline Consumer Healthcare
GlaxoSmithKline Consumer Healthcare is one of the world's largest over-
the-counter consumer healthcare products companies. Its more than 30 well-
known brands include the leading smoking cessation products, Nicorette(R),
NicoDerm(R) and Commit(R), NiQuitin and Nicabate, as well as many medicine
cabinet staples such as Abreva(R), Aquafresh(R), Sensodyne(R) and Tums(R).
GlaxoSmithKline Consumer Healthcare continues to develop innovative
products to help all smokers find their best support system and achieve
their goal of being cigarette free.
GlaxoSmithKline is one of the world's leading research-based
pharmaceutical and consumer healthcare companies. GlaxoSmithKline is
committed to improving the quality of human life by enabling people to do
more, feel better and live longer.
NOTE: GlaxoSmithKline distributes Nicorette(R) gum, Nicoderm(R) patch
and Commit(R) lozenge in the United States. Outside of the U.S., its
smoking cessation patch and lozenge are marketed as Nicabate(R) in
Australia and NiQuitin(R) in other countries.
For more information, please visit the attached link
Contacts: Molly Rabinovitz, GolinHarris
Malesia Dunn, GlaxoSmithKline Consumer Healthcare
SOURCE GlaxoSmithKline Consumer Healthcare